BTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX)

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 22, Justin Zelin from BTIG reiterated a Buy rating on Viking Therapeutics, Inc. (NASDAQ:VKTX) with a price target of $125.

The analyst likes the company’s solid position in the obesity and metabolic disease market. He noted that recent acquisitions by big names such as Pfizer acquiring Metsera underscores the strategic importance of this sector. He highlighted that Viking Therapeutics, Inc. (NASDAQ:VKTX) stands out as one of the few independent companies with an advanced and mature product portfolio, which makes it an attractive partner or acquisition target.

The company’s competitive advantage comes from its differentiated programs. Notably, VK2735 offers potential for monthly dosing. The company also expects to file an IND for an amylin agonist by late 2025. These innovations boost Viking’s chances for good financing and partnership deals.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic and endocrine disorders.

While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.